Chris A. Gentry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chris A. Gentry has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Riley J. Williams
Pharmacy Service, Oklahoma City Veterans Affairs Health Care System, Oklahoma City, OK, USA
13 shared publications George Kurdgelashvili
Department of Medicine, University of Oklahoma Health Sciences Center , Oklahoma City, Oklahoma , USA
6 shared publicationsSharanjeet Thind
Infectious Diseases, Medical Service, Oklahoma City Veterans Affairs Health Care System, Oklahoma City, OK, USA
3 shared publicationsBrian S. Kliewer
Univ Oklahoma Hlth Sci Ctr, Sect Internal Med, Oklahoma City Vet Affairs Hlth Care System, Med Serv, Oklahoma City, OK USA
2 shared publicationsCailyn Evans
Pharmacy Service, Oklahoma City Veterans Affairs Health Care System, Oklahoma City, OK, USA
2 shared publicationsCharles M. Whitman
Pharm Serv, Oklahoma City Vet Affairs Hlth Care Syst, Oklahoma City, OK USA
2 shared publications
Latest Publications
- 11 August 2026
- Published by Elsevier in American Journal of Infection Control
- Vol. 54 (12) , 1264-1270
Characterizing measles IgG-related seroprevalence in the US veteran population during the 2025 West Texas outbreak
- 11 August 2026
- Published by Elsevier in American Journal of Infection Control
- Vol. 54 (12) , 1264-1270
Characterizing measles IgG-related seroprevalence in the US veteran population during the 2025 West Texas outbreak
- 23 March 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 60 (12) , 1182-1188
Variables Associated With Poor Clinical Outcomes in Patients With Serious Fluconazole Non-Susceptible Candida Species Infections
Background: Antifungal resistance among Candida species has become increasingly prevalent in recent years. Objectives: This study aims to identify independent predictors for poor outcomes associated with serious clinical infections caused by fluconazole non-susceptible Candida sp. across the Veterans Health Administration. Methods: This retrospective, observational, nationwide analysis included adults admitted to any Veterans Affairs Medical Center (VAMC) between January 1, 2009, and September 30, 2024, with positive cultures (or rapid diagnostic test) for Candida sp. from otherwise-sterile sites. Multivariate logistic regression assessed associations with the 30-day mortality in patients with these Candida sp. infections, regardless of fluconazole susceptibility. Results: Eligible cases were found from 1613 patients with 1651 culture episodes from otherwise-sterile sites detecting Candida sp. with available fluconazole susceptibility data. Non-susceptible Candida sp. was discovered in 261 of these episodes. Independent variables associated with 30-day mortality in fluconazole non-susceptible infection included reduced serum bicarbonate, thrombocytopenia, recent exposure to the macrolide/tetracycline/clindamycin antibiotics, elevated blood urea nitrogen, and lack of recent outpatient surgery. In the propensity-matched comparison, 30-day mortality between the 2 groups was not statistically significant: 26.6% for episodes with susceptible fluconazole isolates vs 24.9% for non-susceptible episodes (139/522 vs 65/251; P = 0.60). Conclusion and Relevance: Several host-derived physiological markers and recent exposure to protein synthesis inhibitor antibiotics were independent variables associated with 30-day mortality in patients with non-susceptible serious Candida sp. infections. This information may guide clinicians toward strategies to improve the clinical outcomes of these patients.
- 23 March 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 60 (12) , 1182-1188
Variables Associated With Poor Clinical Outcomes in Patients With Serious Fluconazole Non-Susceptible Candida Species Infections
Background: Antifungal resistance among Candida species has become increasingly prevalent in recent years. Objectives: This study aims to identify independent predictors for poor outcomes associated with serious clinical infections caused by fluconazole non-susceptible Candida sp. across the Veterans Health Administration. Methods: This retrospective, observational, nationwide analysis included adults admitted to any Veterans Affairs Medical Center (VAMC) between January 1, 2009, and September 30, 2024, with positive cultures (or rapid diagnostic test) for Candida sp. from otherwise-sterile sites. Multivariate logistic regression assessed associations with the 30-day mortality in patients with these Candida sp. infections, regardless of fluconazole susceptibility. Results: Eligible cases were found from 1613 patients with 1651 culture episodes from otherwise-sterile sites detecting Candida sp. with available fluconazole susceptibility data. Non-susceptible Candida sp. was discovered in 261 of these episodes. Independent variables associated with 30-day mortality in fluconazole non-susceptible infection included reduced serum bicarbonate, thrombocytopenia, recent exposure to the macrolide/tetracycline/clindamycin antibiotics, elevated blood urea nitrogen, and lack of recent outpatient surgery. In the propensity-matched comparison, 30-day mortality between the 2 groups was not statistically significant: 26.6% for episodes with susceptible fluconazole isolates vs 24.9% for non-susceptible episodes (139/522 vs 65/251; P = 0.60). Conclusion and Relevance: Several host-derived physiological markers and recent exposure to protein synthesis inhibitor antibiotics were independent variables associated with 30-day mortality in patients with non-susceptible serious Candida sp. infections. This information may guide clinicians toward strategies to improve the clinical outcomes of these patients.
- 13 March 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 60 (11) , 1058-1065
Predictors for the Development of Invasive Infection of Fluconazole Non-Susceptible or Echinocandin Non-Susceptible Candida Species Across the Veterans Health Administration
Background: Antifungal-resistant Candida species have become increasingly prevalent in recent years, posing significant therapeutic challenges in the inpatient setting. Despite their clinical relevance, comprehensive data evaluating risk factors for the development of invasive infections caused by Candida sp. with antifungal resistance are limited. Objective: This study aims to identify independent predictors for the development of invasive clinical infections caused by fluconazole-resistant or echinocandin-resistant Candida sp. in hospitalized veterans across the United States Veterans Health Administration. Methods: This retrospective, observational, nationwide analysis included adults ≥18 years admitted to any Veterans Affairs Medical Center between January 1, 2009, and September 30, 2024, with culture-positive or rapid diagnostic test-confirmed invasive Candida sp. infection from otherwise-sterile sites. Data were gathered on baseline demographics, baseline laboratory data, comorbid conditions, and exposure to antibacterial agents, antifungal agents, β-Hydroxy β-methylglutaryl-CoA (HMG-CoA) reductase inhibitors, and immunosuppressant drug therapy. Univariate and multivariate logistic regression models were used to assess associations between clinical variables and the development of invasive fluconazole-resistant and echinocandin-resistant Candida sp. infections. Results: Eligible cases were found from 25 Veterans Affairs Medical Center facilities; 1651 episodes had available fluconazole susceptibility data, and 1117 episodes had echinocandin susceptibility data. Fluconazole non-susceptibility was independently associated with at least 7 days of recent exposure to either fluconazole or an echinocandin, among a few other variables. Echinocandin resistance, while less common, was strongly linked to the receipt of dialysis, prolonged Gram-positive antibacterial exposure, and any prior antifungal use. Conclusions and Relevance: These findings can inform antifungal stewardship efforts to curb the rise of resistant Candida sp.
- 13 March 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 60 (11) , 1058-1065
Predictors for the Development of Invasive Infection of Fluconazole Non-Susceptible or Echinocandin Non-Susceptible Candida Species Across the Veterans Health Administration
Background: Antifungal-resistant Candida species have become increasingly prevalent in recent years, posing significant therapeutic challenges in the inpatient setting. Despite their clinical relevance, comprehensive data evaluating risk factors for the development of invasive infections caused by Candida sp. with antifungal resistance are limited. Objective: This study aims to identify independent predictors for the development of invasive clinical infections caused by fluconazole-resistant or echinocandin-resistant Candida sp. in hospitalized veterans across the United States Veterans Health Administration. Methods: This retrospective, observational, nationwide analysis included adults ≥18 years admitted to any Veterans Affairs Medical Center between January 1, 2009, and September 30, 2024, with culture-positive or rapid diagnostic test-confirmed invasive Candida sp. infection from otherwise-sterile sites. Data were gathered on baseline demographics, baseline laboratory data, comorbid conditions, and exposure to antibacterial agents, antifungal agents, β-Hydroxy β-methylglutaryl-CoA (HMG-CoA) reductase inhibitors, and immunosuppressant drug therapy. Univariate and multivariate logistic regression models were used to assess associations between clinical variables and the development of invasive fluconazole-resistant and echinocandin-resistant Candida sp. infections. Results: Eligible cases were found from 25 Veterans Affairs Medical Center facilities; 1651 episodes had available fluconazole susceptibility data, and 1117 episodes had echinocandin susceptibility data. Fluconazole non-susceptibility was independently associated with at least 7 days of recent exposure to either fluconazole or an echinocandin, among a few other variables. Echinocandin resistance, while less common, was strongly linked to the receipt of dialysis, prolonged Gram-positive antibacterial exposure, and any prior antifungal use. Conclusions and Relevance: These findings can inform antifungal stewardship efforts to curb the rise of resistant Candida sp.
- Open Access
- 24 April 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1509941
Association of SSRI and SNRI use with incidence of cardiovascular events in veterans with giant cell arteritis and polymyalgia rheumatica
The leading cause of death in patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) is cardiovascular disease. The objective of this study was to determine whether the use of selective serotonin reuptake inhibitors (SSRI) and serotonin norepinephrine reuptake inhibitors (SNRI) in veterans with GCA and PMR could have a cardio-modulatory effect as compared to nonuse. Patients with GCA and PMR were identified through the Veterans Affairs Informatics and Computing Infrastructure. After a 2:1 propensity score matching for SSRI or SNRI users, we identified nonusers with similar covariates. We then applied a multivariate logistic regression (MLR), to calculate the odds ratio (OR) for cardiovascular event (CVE) outcomes within 5 years after the index date. Related hazard ratios (HR) were also calculated to validate the discovery of our findings. We identified 2249 patients with GCA and 3906 patients with PMR. Among patients with GCA, 174 (27%) SSRI users had incident cardiovascular disease as compared to 47 (28%) SNRI users and 277 (19%) nonusers; in the PMR cohort, 108 (13%) were SSRI users compared to 71 (15%) SNRI users and 255 (11%) nonusers. The adjusted ORs of the CVE outcome associated with venlafaxine (2.44, p=0.01) and sertraline (1.45, p=0.04) were significantly greater than 1 in GCA, with similar results observed in the PMR cohort (2.01, p=0.02, and 1.45, p=0.04, respectively). Cox-regression analysis was also conducted, and the hazard ratios were qualitatively consistent with the MLR analysis. In conclusion, the adjusted risk of CVE in patients with GCA or PMR using either venlafaxine or sertraline was higher than that in the non-exposed groups.
- 24 April 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1509941
Open AccessAssociation of SSRI and SNRI use with incidence of cardiovascular events in veterans with giant cell arteritis and polymyalgia rheumatica
The leading cause of death in patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) is cardiovascular disease. The objective of this study was to determine whether the use of selective serotonin reuptake inhibitors (SSRI) and serotonin norepinephrine reuptake inhibitors (SNRI) in veterans with GCA and PMR could have a cardio-modulatory effect as compared to nonuse. Patients with GCA and PMR were identified through the Veterans Affairs Informatics and Computing Infrastructure. After a 2:1 propensity score matching for SSRI or SNRI users, we identified nonusers with similar covariates. We then applied a multivariate logistic regression (MLR), to calculate the odds ratio (OR) for cardiovascular event (CVE) outcomes within 5 years after the index date. Related hazard ratios (HR) were also calculated to validate the discovery of our findings. We identified 2249 patients with GCA and 3906 patients with PMR. Among patients with GCA, 174 (27%) SSRI users had incident cardiovascular disease as compared to 47 (28%) SNRI users and 277 (19%) nonusers; in the PMR cohort, 108 (13%) were SSRI users compared to 71 (15%) SNRI users and 255 (11%) nonusers. The adjusted ORs of the CVE outcome associated with venlafaxine (2.44, p=0.01) and sertraline (1.45, p=0.04) were significantly greater than 1 in GCA, with similar results observed in the PMR cohort (2.01, p=0.02, and 1.45, p=0.04, respectively). Cox-regression analysis was also conducted, and the hazard ratios were qualitatively consistent with the MLR analysis. In conclusion, the adjusted risk of CVE in patients with GCA or PMR using either venlafaxine or sertraline was higher than that in the non-exposed groups.
- Open Access
- 24 August 2023
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (2) , 330-337
Characteristics and Outcomes of US Veterans With Immunocompromised Conditions at High Risk of SARS-CoV-2 Infection With or Without Receipt of Oral Antiviral Agents
Objectives: Molnupiravir and nirmatrelvir-ritonavir were the first oral antiviral agents to demonstrate reduced hospitalization or death in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but patients with immunocompromised conditions were not well-represented. The objective of this study was to characterize and compare the clinical outcomes of US veterans with immunocompromised conditions prescribed oral antivirals with those who did not receive oral antivirals for mild-to-moderate SARS-CoV-2 active infection. Methods: This was a retrospective, observational, nationwide propensity-matched analysis of US veterans with immunocompromised conditions who developed documented SARS-CoV-2 infection. The primary outcome was the composite of any hospitalization or death within 30 days of diagnosis. Secondary outcomes included 30-day comparative rates of (1) any hospitalization, (2) death, (3) intensive care requirement, and (4) subset analyses of outcomes by oral antiviral used and vaccination status. Results: The composite primary outcome was significantly lower in patients receiving oral antiviral therapy compared with those who did not (23/390 [5.9%] vs 57/390 [14.6%]; odds ratio, 0.37; 95% confidence interval, .22–.61). This difference was driven largely by fewer deaths in the oral antiviral group (1/390 [0.3%] vs 19/390 [4.9%]; odds ratio, 0.05; 95% confidence interval, .007–.38). There was no significant difference in rate of intensive care requirement. The composite outcome was improved in vaccinated patients (completing the first series or first booster dose) who received oral antiviral agents compared with those who did not receive oral antiviral agents. Compared with those prescribed nirmatrelvir-ritonavir, patients given molnupiravir were older, had a higher incidence of cautions/contraindications, greater prevalence of tobacco use, and more cardiovascular complications. Conclusions: Use of molnupiravir or nirmatrelvir-ritonavir was associated with lower incidences of hospitalization or death within 30 days of diagnosis in US veterans with immunocompromised conditions, regardless of vaccination status. These findings support the use of either oral antiviral in this patient population.
- 24 August 2023
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (2) , 330-337
Open AccessCharacteristics and Outcomes of US Veterans With Immunocompromised Conditions at High Risk of SARS-CoV-2 Infection With or Without Receipt of Oral Antiviral Agents
Objectives: Molnupiravir and nirmatrelvir-ritonavir were the first oral antiviral agents to demonstrate reduced hospitalization or death in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but patients with immunocompromised conditions were not well-represented. The objective of this study was to characterize and compare the clinical outcomes of US veterans with immunocompromised conditions prescribed oral antivirals with those who did not receive oral antivirals for mild-to-moderate SARS-CoV-2 active infection. Methods: This was a retrospective, observational, nationwide propensity-matched analysis of US veterans with immunocompromised conditions who developed documented SARS-CoV-2 infection. The primary outcome was the composite of any hospitalization or death within 30 days of diagnosis. Secondary outcomes included 30-day comparative rates of (1) any hospitalization, (2) death, (3) intensive care requirement, and (4) subset analyses of outcomes by oral antiviral used and vaccination status. Results: The composite primary outcome was significantly lower in patients receiving oral antiviral therapy compared with those who did not (23/390 [5.9%] vs 57/390 [14.6%]; odds ratio, 0.37; 95% confidence interval, .22–.61). This difference was driven largely by fewer deaths in the oral antiviral group (1/390 [0.3%] vs 19/390 [4.9%]; odds ratio, 0.05; 95% confidence interval, .007–.38). There was no significant difference in rate of intensive care requirement. The composite outcome was improved in vaccinated patients (completing the first series or first booster dose) who received oral antiviral agents compared with those who did not receive oral antiviral agents. Compared with those prescribed nirmatrelvir-ritonavir, patients given molnupiravir were older, had a higher incidence of cautions/contraindications, greater prevalence of tobacco use, and more cardiovascular complications. Conclusions: Use of molnupiravir or nirmatrelvir-ritonavir was associated with lower incidences of hospitalization or death within 30 days of diagnosis in US veterans with immunocompromised conditions, regardless of vaccination status. These findings support the use of either oral antiviral in this patient population.
- 10 February 2023
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 61 (4) , 106752
Propensity-matched analysis of the protective effect of ticagrelor versus clopidogrel on the risk of developing Staphylococcus aureus bacteremia
- 10 February 2023
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 61 (4) , 106752
Propensity-matched analysis of the protective effect of ticagrelor versus clopidogrel on the risk of developing Staphylococcus aureus bacteremia
- 1 February 2023
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 61 (4) , 106743
Staphylococcus aureus bacteraemia treatment outcomes in patients receiving ticagrelor vs a propensity-matched cohort receiving clopidogrel
- 1 February 2023
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 61 (4) , 106743
Staphylococcus aureus bacteraemia treatment outcomes in patients receiving ticagrelor vs a propensity-matched cohort receiving clopidogrel
- 23 January 2023
- Published by Elsevier in Journal of Infection
- Vol. 86 (3) , 248-255
Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents
- 23 January 2023
- Published by Elsevier in Journal of Infection
- Vol. 86 (3) , 248-255
Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents
- 11 September 2022
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 365 (1) , 19-25
Development of SARS-CoV-2 infection in patients with rheumatic conditions on hydroxychloroquine monotherapy vs. patients without rheumatic conditions: A retrospective, propensity-matched cohort study
- 11 September 2022
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 365 (1) , 19-25
Development of SARS-CoV-2 infection in patients with rheumatic conditions on hydroxychloroquine monotherapy vs. patients without rheumatic conditions: A retrospective, propensity-matched cohort study
- 1 June 2021
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 100 (2) , 115308
Continued decline in the prevalence of the Clostridioides difficile BI/NAP1/027 strain across the United States Veterans Health Administration
- 1 June 2021
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 100 (2) , 115308
Continued decline in the prevalence of the Clostridioides difficile BI/NAP1/027 strain across the United States Veterans Health Administration